ASH 2023: MRD Highlights in BioPharma Drug Development

Read More

clonoSEQ Expands to Third Indication for Chronic Lymphocytic Leukemia

For the first time, the FDA clears clonoSEQ for use as a blood-based test. Patients living with the most common type of leukemia have a new and convenient way to get answers about their disease and remission status.